October 2022 - Page 11 of 22

TuesdayOct 18, 2022 12:40 pm

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports Assay Results from Iska Iska Drills

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has been conducting an ongoing drilling program at its Iska Iska silver-tin polymetallic project and is reporting on two diamond drill holes. According to the announcement, drill hole DSB-36 collared 400m southeast of the Santa Barbara adit, tested the extension of the core of the high-grade feeder zone at Santa Barbara while hole DSB-34 tested the potential southwest limits of the high-grade feeder zone. Eloro noted that so far 118 drill holes have…

TuesdayOct 18, 2022 12:32 pm

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) CEO Joins Hercules Electric Mobility CEO to Discuss New Deal

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean-technology company developing transformative power conversion technologies and control system solutions for next-generation EVs and electrical systems, has signed an agreement with Hercules Electric Mobility to bring customizable electric mobility products to market. Leaders from the two companies — HLRTF CEO Don Currie and Hercules Electric Mobility CEO James Breyer — discussed the partnership on a recent Proactive interview with host Steve Darling, noting that the partnership is aimed at integrating the latest technologies into new, innovative products and accelerating the path to market. To view the full interview, visit https://ibn.fm/BzwI1 To view…

TuesdayOct 18, 2022 12:00 pm

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Releases Positive Results From Silver-Tin Polymetallic Project in Bolivia

Eloro Resources is an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru, and Quebec Company released positive results from 21 diamond drill holes at Iska Iska Bolivia project revealing silver, tin, zinc, lead New borehole geophysical data expanding Santa Barbara high-grade feeder zone with potential strike length of at least 2 kilometers Eloro has option to acquire 99 percent interest in the Iska Iska property, owns 82 percent interest in La Victoria Gold/Silver project in Peru Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), a publicly traded exploration and mine development company…

TuesdayOct 18, 2022 11:15 am

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Expands Production Facilities; Names CFO to Oversee Company’s Next Growth Stage

The Renewable Natural Gas (“RNG”) market is forecast to grow to an annual market size of $72.13 billion by 2027 EverGen purchased a 66% stake in Albert-based agri operation, GrowTEC for a gross consideration of $2.1 million EverGen are in the process of building out the required infrastructure needed to inject the company’s RNG production into the local electric grid Elsewhere, the company also announced that Sean Hennessey would take over the vacant CFO position, substituting the company’s existing interim CFO, Natasha Monk On October 9th, Chevron announced their intention to produce and market dairy biomethane as a renewable natural…

TuesdayOct 18, 2022 10:30 am

Correlate Infrastructure Partners Inc. (CIPI) Expanding as Solar Adoption is Projected to Grow by 30% in 2022

Correlate’s strategic investments in clean electrification solutions and commercial solar infrastructure have earned the company a growing customer base, and an opportunity pipeline of over $100 million in commercial projects The company recognizes the rise in EV and solar adoption and looks to tap into this growth to increase its revenues, brand equity, and market reach Todd Michaels, the company’s Founder, President, and CEO, acknowledges that “It has never been a better time for [our] business” With solar and EV adoption set to grow significantly this year, and with the company’s recent acquisition and planned acquisitions, Correlate is set to…

TuesdayOct 18, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate

Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDA Since the acquisition, the company has completed IND enabling studies and all cohorts for Phase I SAD and MAD clinical trials for its lead drug candidate In pre-clinical studies PRV-002 has demonstrated equivalent, if not superior neuroprotective effects compared to related neurosteroids, offering proof of reduced behavioral pathology associated with brain injury symptoms, easily crossing the blood-brain barrier to rapidly eliminate…

TuesdayOct 18, 2022 9:00 am

As Mercedes Sees Market Turning to EVs, Hillcrest Energy Technologies Ltd.’s (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) Charging Technology Becomes Increasingly Important

The IEA sees EV sales hitting a record in 2022 after doubling in 2021 from 2020, while noting the lack of charging infrastructure as an obstacle for adoption Hillcrest Energy has developed a new class of inverters that convert DC output from batteries into AC input used by motors in EVs Hillcrest filed a patent application for new tech that eliminates the need for EVs to require and onboard charger, allowing for faster, anywhere charging During an interview last week with CNBC’s Jim Cramer, Mercedes-Benz CEO Ola Kallenius said he is seeing the market for luxury vehicles progressively turning towards…

MondayOct 17, 2022 2:34 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone…

MondayOct 17, 2022 1:35 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

MondayOct 17, 2022 1:05 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

Site Search

Company Search

Month: October 2022